

## List of Figures

<b>Figure 1.1</b> Factors influencing bioavailability of drugs in oral drug delivery.....	4
<b>Figure 1.2</b> Various Strategies to improve bioavailability of drugs.....	5
<b>Figure 1.3</b> Transporters are localized in the apical and basolateral membrane.....	23
<b>Figure 1.4</b> Different Mechanism of actions of natural bioenhancers.....	33
<b>Figure 1.5</b> Drug Metabolizing enzymes inhibited by Piperine.....	34
<b>Figure 3.1</b> Mechanism of action of Acyclovir.....	80
<b>Figure 3.2</b> Mechanism of action of Saquinavir.....	83
<b>Figure 4.1</b> Cause and Effect diagram to identify sources for uncertainty.....	96
<b>Figure 4.2</b> Plasma Extraction Procedure for ACV.....	101
<b>Figure 4.3</b> Chromatogram of blank, blank sample cell line, standard and sample.....	102
<b>Figure 4.4</b> Chromatogram of blank, standard and plasma sample with MS2 of ACV...	103
<b>Figure 4.5</b> Cause and effect diagram to identify the sources of uncertainty.....	104
<b>Figure 4.6</b> Diffusion cell design for ex-vivo permeation studies.....	107
<b>Figure 4.7</b> Transwell Plate containing Caco-2 cell lines.....	108
<b>Figure 4.8</b> Standard residual plot of four different series representing absence of outliers in all different concentration levels.....	118
<b>Figure 4.9</b> Accuracy profile of acyclovir determination in A) tablets B) skin cream C) eye ointment D) injection obtained after application of linear regression using calibration standards prepared with the matrix. The plain line is the relative bias, the dashed lines are the 95% $\beta$ -expectation tolerance limits and the dotted curves represent the acceptance limits ( $\pm 5\%$ ). The dots represent the relative back calculated concentrations of the validation standards.....	120
<b>Figure 4.10</b> Standard residual plot confirming absence of outliers in determination of accuracy of A) tablets B) skin cream C) eye ointment D) injection.....	122
<b>Figure 4.11</b> Uncertainty profile for acyclovir determination in A) tablets B) skin cream C) eye ointment D) injection representing different components contributing in overall uncertainty and showing maximum effect due to concentration of sample.....	132
<b>Figure 4.12</b> Standard residual plot of representing absence of outliers at different concentration levels.....	135

<b>Figure 4.13</b> Accuracy profile of ACV obtained after application of linear regression using calibration standards prepared with the matrix. The plain line is the relative bias, the dashed lines are the 95% $\beta$ -expectation tolerance limits and the dotted curves represent the acceptance limits ( $\pm 5\%$ ). The dots represent the relative back-calculated concentrations of the validation standards.....	138
<b>Figure 4.14</b> Uncertainty profile representing different components contributing in overall uncertainty.....	143
<b>Figure 4.15</b> FTIR spectrum of (A) ACV (B) QU (C) Sil (D) LT (E) ACV:QU (F) ACV:Sil (G) ACV:LT for compatibility studies.....	145
<b>Figure 4.16</b> DSC thermogram of A) ACV B) QU C) Sil D) LT E) ACV:QU F) ACV:Sil G) ACV:LT.....	147
<b>Figure 4.17</b> Release time profile of the ACV and ACV:QU binary system.....	149
<b>Figure 4.18</b> Release time profile of the ACV and ACV:Sil binary system.....	150
<b>Figure 4.19</b> Release time profile of the ACV and ACV:LT binary system.....	150
<b>Figure 4.20</b> Cellular Uptake of ACV and binary system at different time points (0hr, 0.5hr, 1hr).....	152
<b>Figure 4.21</b> Effect of different ratios of Quercetin on TEER Values of Caco-2 cell line..	153
<b>Figure 4.22</b> Effect of different ratios of Silibinin on TEER Values of Caco-2 cell line..	153
<b>Figure 4.23</b> Effect of different ratios of Luteolin on TEER Values of Caco-2 cell line..	154
<b>Figure 4.24</b> Release time profile of ACV and ACV:QU binary system in Caco-2 cell lines.....	154
<b>Figure 4.25</b> Release time profile of ACV and ACV:Sil binary system in Caco-2 cell lines.....	155
<b>Figure 4.26</b> Release time profile of the ACV and ACV:LT binary system in Caco-2 cell lines.....	155
<b>Figure 4.27</b> Papp comparison of ACV and ACV:QU different weight ratios from AP to BL side.....	156
<b>Figure 4.28</b> Papp comparison of ACV and ACV:Sil different weight ratios from AP to BL side.....	157
<b>Figure 4.29</b> Papp comparison of ACV and ACV:LT different weight ratios from AP to BL side.....	157

<b>Figure 4.30</b> Enhancement Ratio (ER) comparison for different bioenhancers with maximum Papp.....	158
<b>Figure 4.31</b> Mean Plasma Concentration and Time profile for ACV, ACV:QU, ACV:Sil and ACV:LT.....	159
<b>Figure 4.32</b> Semi Log Plot for Concentration vs Time for ACV, ACV:QU, ACV:Sil, ACV:LT.....	160
<b>Figure 4.33</b> Enhancement Ratio (ER) comparison for different bioenhancers with respect to AUC.....	160
<b>Figure 4.34</b> Ln concentration time profile including absorption and elimination phase for ACV.....	161
<b>Figure 4.35</b> Ln concentration time profile including absorption and elimination phase for ACV:QU.....	161
<b>Figure 4.36</b> Ln concentration time profile including absorption and elimination phase for ACV:Sil.....	162
<b>Figure 4.37</b> Ln concentration time profile including absorption and elimination phase for ACV:LT.....	162
<b>Figure 5.1</b> Plasma Extraction Procedure for SQU.....	172
<b>Figure 5.2</b> Chromatogram of Blank, Blank plasma, Standard and Plasma Sample.....	173
<b>Figure 5.3</b> FTIR spectrum of (A) SQU (B) QU (C) Sil (D) LT (E) SQU:QU (F) SQU:Sil (G) SQU:LT for compatibility studies.....	186
<b>Figure 5.4</b> DSC thermogram of (A) SQU (B) QU (C) Sil (D) LT (E) SQU:QU (F) SQU:Sil (G) SQU:LT for compatibility studies.....	188
<b>Figure 5.5</b> Time profile for permeation of the SQU and SQU:QU from the intestinal tissue.....	191
<b>Figure 5.6</b> Time profile for permeation of the SQU and SQU:Sil from the intestinal tissue.....	191
<b>Figure 5.7</b> Time profile for permeation of the SQU and SQU:Sil from the intestinal tissue.....	192
<b>Figure 5.8</b> Cellular Uptake of SQU and binary system at different time points (0hr, 0.5hr, 1hr) .....	194
<b>Figure 5.9</b> Effect of different ratios of Quercetin on TEER Values of Caco-2 cell line...	195

<b>Figure 5.10</b> Effect of different ratios of Silibinin on TEER Values of Caco-2 cell line...	195
<b>Figure 5.11</b> Effect of different ratios of Luteolin on TEER Values of Caco-2 cell line...	196
<b>Figure 5.12</b> Release time profile of SQU and SQU:QU binary system in Caco-2 cell lines.....	196
<b>Figure 5.13</b> Release time profile of SQU and SQU:Sil binary system in Caco-2 cell lines.....	197
<b>Figure 5.14</b> Release time profile of SQU and SQU:LT binary system in Caco-2 cell lines.....	197
<b>Figure 5.15</b> Papp comparison of SQU and SQU:QU different weight ratios from AP to BL side.....	198
<b>Figure 5.16</b> Papp comparison of SQU and SQU:Sil different weight ratios from AP to BL side.....	198
<b>Figure 5.17</b> Papp comparison of SQU and SQU:LT different weight ratios from AP to BL side.....	199
<b>Figure 5.18</b> Time profile for mean plasma concentration for SQU and SQU:QU.....	200
<b>Figure 5.19</b> Time profile for mean plasma concentration for SQU and SQU:Sil.....	201
<b>Figure 5.20</b> Time profile for mean plasma concentration for SQU and SQU:LT.....	201
<b>Figure 5.21</b> Semi Log Plot for Concentration vs Time for SQU, SQU:QU, SQU:Sil, SQU:LT.....	202
<b>Figure 5.22</b> Enhancement Ratio (ER) comparison for different bioenhancers with respect to AUC.....	203
<b>Figure 5.23</b> Ln concentration time profile including absorption and elimination phase for SQU.....	203
<b>Figure 5.24</b> Ln concentration time profile including absorption and elimination phase for SQU:QU.....	204
<b>Figure 5.25</b> Ln concentration time profile including absorption and elimination phase for SQU:Sil.....	204
<b>Figure 5.26</b> Ln concentration time profile including absorption and elimination phase for SQU:Sil.....	205
<b>Figure 6.1</b> Chromatogram of ACV.....	222
<b>Figure 6.2</b> Mass spectra of ACV.....	223

<b>Figure 6.3</b> Chromatogram of Blank, Blank sample, Standard and cell line sample.....	223
<b>Figure 6.4</b> Comparison of mean cumulative amount of ACV released in presence and absence of QU per unit area of skin.....	225
<b>Figure 6.5</b> Comparison of mean cumulative amount of ACV released in presence and absence of QU per unit area of skin.....	226
<b>Figure 6.6</b> Comparison of mean cumulative amount of ACV released in presence and absence of QU per unit area of skin.....	226
<b>Figure 6.7</b> Comparison of Flux of ACV in the presence and absence of different ratios of bioenhancers.....	227
<b>Figure 6.8</b> Comparison of amount of drug retain in the skin.....	228
<b>Figure 6.9</b> Application of the cream on the abdominal part of the rat.....	229
<b>Figure 6.10</b> Comparison of the % unabsorbed drug in the presence and absence of QU..	230
<b>Figure 6.11</b> Comparison of the % unabsorbed drug in the presence and absence of Sil...	230
<b>Figure 6.12</b> Comparison of the % unabsorbed drug in the presence and absence of LT...	231
<b>Figure 6.13</b> Amount of drug permeated with time in HaCat cell lines at different concentrations of LT.....	232
<b>Figure 6.14</b> Amount of drug permeated with time in HaCat cell lines at different concentrations of QU.....	232
<b>Figure 6.15</b> Amount of drug permeated with time in HaCat cell lines at different concentrations of Sil.....	233
<b>Figure 6.16</b> Comparison of ER of three different bioenhancers.....	233
<b>Figure 6.17</b> Cell viability in MTT Assay.....	234
<b>Figure 6.18</b> mRNA level at different concentration of Sil from (0-5%).....	235
<b>Figure 6.19</b> mRNA level at different concentration of QU from (0-5%).....	235
<b>Figure 6.20</b> mRNA level at different concentration of LT from (0-5%).....	236